French Biotech Brenus Pharma Raises €11 Million, Total Funding Reaches €38 Million

With this latest investment, the company's total funding has reached €38 million since it was founded.

The funding round received strong support from existing investors, including Angelor, UI Investissement, Crédit Agricole, Noshaq, Orsa, BIO JAG, and Bpifrance, showing their continued confidence in Brenus Pharma's technology and growth plans.

“We are proud to welcome international investors who share our vision, and grateful for the continued confidence of our existing backers. This funding will enable us to complete the Phase I program and continue accelerating our in vivo immunotherapy platform by advancing our next drug candidate. I would also like to thank our historical investors for their trust and support,” said Paul Bravetti, CEO of Brenus Pharma.

“We couldn’t be more confident in our first investment in France. The company combines truly differentiated technology with early clinical validation and team executing at pace. This is exactly the type of European innovation we want to support as we expand our portfolio internationally. We look forward to supporting Brenus as it advances its innovation toward a new treatment for patients with significant unmet medical needs,” said Dae Kyeong Bae, Senior Vice President at Korea Omega Investment Corp.

Founded in 2019 by Benoit Pinteur, Brenus Pharma is developing an off-the-shelf immunotherapy platform that helps the body's immune system detect and fight cancer more effectively. Its technology is designed to make cancer cells easier for the immune system to recognize.

The company's technology copies the way tumour proteins appear, helping the immune system identify and attack cancer cells. It is designed to treat hard-to-treat solid tumours and can adapt as the tumour changes, offering a new option where current cancer treatments are less effective.

Read Also- AI-Powered Modo Energy Expands with €14.9 Million Growth Investment